ARB-1598 (TLR9 Agonist)

TLR9 agonists are a novel approach to immune reactivation in patients with chronic HBV. By stimulating cellular TLRs we expect to be able to elicit an innate immune response that leads to the production of cellular proteins that target viral infections.


On December 30, 2014, Arbutus Inc. entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to 6 different series of compounds, including the product candidate ARB-1598. We have conducted additional research and analysis on ARB-1598, which has led to the decision to discontinue the ARB-1598 development program.